Innate Pharma Cash And Equivalents vs. Shares Owned By Institutions
| IPHA Stock | USD 2.12 0.04 1.85% |
For Innate Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Innate Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Innate Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Innate Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Innate Pharma over time as well as its relative position and ranking within its peers.
Innate |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.44) | Revenue Per Share | Quarterly Revenue Growth (0.69) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Innate Pharma Shares Owned By Institutions vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Innate Pharma's current stock value. Our valuation model uses many indicators to compare Innate Pharma value to that of its competitors to determine the firm's financial worth. Innate Pharma is rated below average in cash and equivalents category among its peers. It is rated below average in shares owned by institutions category among its peers . The ratio of Cash And Equivalents to Shares Owned By Institutions for Innate Pharma is about 362,794,118 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innate Pharma's earnings, one of the primary drivers of an investment's value.Innate Shares Owned By Institutions vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Innate Pharma |
| = | 123.35 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Innate Pharma |
| = | 0.34 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Innate Shares Owned By Institutions Comparison
Innate Pharma is currently under evaluation in shares owned by institutions category among its peers.
Innate Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Innate Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Innate Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Innate Pharma's change in net profit over the period of time. It can combine multiple indicators of Innate Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 569.2 K | 597.7 K | |
| Operating Income | -11.4 M | -12 M | |
| Income Before Tax | -6.8 M | -7.2 M | |
| Total Other Income Expense Net | 5.9 M | 6.2 M | |
| Net Loss | -6.8 M | -7.2 M | |
| Income Tax Expense | -11.2 M | -10.6 M | |
| Net Loss | -6.8 M | -7.2 M | |
| Net Loss | -52.3 M | -49.7 M | |
| Net Interest Income | 2.9 M | 3.1 M | |
| Interest Income | 3.7 M | 4.6 M | |
| Change To Netincome | 7 M | 7.3 M | |
| Net Loss | (0.09) | (0.11) | |
| Income Quality | 4.95 | 5.19 | |
| Net Income Per E B T | 1.54 | 1.46 |
Innate Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Innate Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Innate Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Innate Pharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Innate Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Use Investing Themes to Complement your Innate Pharma position
In addition to having Innate Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Air Thematic Idea Now
Air
Companies specializing in air services and air delivery. The Air theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Air Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
To fully project Innate Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Innate Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Innate Pharma's income statement, its balance sheet, and the statement of cash flows.